$1.08 Billion is the total value of Sofinnova Investments, Inc.'s 150 reported holdings in Q1 2020. The portfolio turnover from Q4 2019 to Q1 2020 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| RYTM | Exit | Rhythm Pharmaceuticals Inc | $0 | – | -21,319 | -100.0% | -0.04% | – |
| HALO | Exit | Halozyme Therapeutics Inc | $0 | – | -72,481 | -100.0% | -0.09% | – |
| DRNA | Exit | Dicerna Pharmaceuticals Inc | $0 | – | -159,512 | -100.0% | -0.25% | – |
| APLT | Exit | Applied Therapeutics Inc | $0 | – | -134,825 | -100.0% | -0.26% | – |
| FOMX | Exit | Foamix Pharmaceuticals Ltd | $0 | – | -1,162,176 | -100.0% | -0.28% | – |
| ORTX | Exit | Orchard Therapeutics PLCadr | $0 | – | -283,406 | -100.0% | -0.28% | – |
| XBIT | Exit | XBiotech Inc | $0 | – | -240,995 | -100.0% | -0.32% | – |
| FTSV | Exit | Forty Seven Inc | $0 | – | -138,643 | -100.0% | -0.39% | – |
| SGEN | Exit | Seattle Genetics Inc | $0 | – | -50,000 | -100.0% | -0.41% | – |
| ARQL | Exit | ArQule Inc | $0 | – | -387,469 | -100.0% | -0.56% | – |
| Exit | Alexion Pharmaceuticals Inccall | $0 | – | -75,000 | -100.0% | -0.58% | – | |
| DERM | Exit | Dermira Inc | $0 | – | -545,466 | -100.0% | -0.60% | – |
| Exit | Medicines Coput | $0 | – | -110,000 | -100.0% | -0.67% | – | |
| MGNX | Exit | MacroGenics Inc | $0 | – | -1,173,882 | -100.0% | -0.92% | – |
| MRTX | Exit | Mirati Therapeutics Inc | $0 | – | -108,383 | -100.0% | -1.01% | – |
| REGN | Exit | Regeneron Pharmaceuticals Inc | $0 | – | -50,086 | -100.0% | -1.36% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-05-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Natera, Inc. | 26 | Q2 2024 | 20.5% |
| Ascendis Pharma A/S | 26 | Q2 2024 | 27.9% |
| NuCana plc | 25 | Q1 2024 | 15.2% |
| Y-mAbs Therapeutics, Inc. | 24 | Q2 2024 | 6.5% |
| SYNDAX PHARMACEUTICALS INC | 22 | Q2 2024 | 2.3% |
| Synlogic Inc. (fmrly Mirna) | 22 | Q2 2023 | 0.9% |
| PDS Biotechnology Corporation | 22 | Q2 2024 | 0.1% |
| Nucana PLC | 21 | Q1 2024 | 9.7% |
| ObsEva SA | 20 | Q4 2022 | 11.0% |
| Nextcure, Inc | 20 | Q2 2024 | 10.8% |
View Sofinnova Investments, Inc.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| OTONOMY, INC.Sold out | February 14, 2022 | 0 | 0.0% |
View Sofinnova Investments, Inc.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| N-PX | 2024-08-28 |
| 13F-HR/A | 2024-08-15 |
| 13F-HR/A | 2024-08-14 |
| 13F-HR | 2024-08-09 |
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-11 |
| 13F-HR | 2023-02-14 |
View Sofinnova Investments, Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.